Tigecycline
- Generic Name
- Tigecycline
- Brand Names
- Tygacil, Tigecycline Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39N5O8
- CAS Number
- 220620-09-7
- Unique Ingredient Identifier
- 70JE2N95KR
- Background
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
- Indication
For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, ...
- Associated Conditions
- Bacterial Infections, Community Acquired Pneumonia (CAP), Complicated Intra-Abdominal Infections (cIAIs), Complicated Skin and Skin Structure Infection
- Associated Therapies
- -
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 550
- Registration Number
- NCT00368537
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 1061
- Registration Number
- NCT00366249
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 473
- Registration Number
- NCT00230971
Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 503
- Registration Number
- NCT00228410
Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT00205816
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 467
- Registration Number
- NCT00195351
Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00136201
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-04-21
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 850
- Registration Number
- NCT00081744
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 434
- Registration Number
- NCT00081575
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-04-07
- Last Posted Date
- 2008-08-04
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 430
- Registration Number
- NCT00080496
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath